Skip to content

Inspection Record

ID Biomedical Corporation of Quebec — FDA 483 Findings

US FDAInspected 2022-05-20Published 2026-10-26 5 findingsOther quality systemDeviation, CAPA, and investigationComplaint and recall handlingEquipment and facilityAseptic processing and sterility assurance

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

The sampling ofthe is not representative of use.

2Deviation, CAPA, and investigation

The following investigation was inadequate.

3Complaint and recall handling

The following complaint records were found incomplete and/or deficient: a.

4Equipment and facility

Preventative maintenance activities were incomplete.

5Aseptic processing and sterility assurance

Procedures designed to prevent microbial contamination ofdrug products purporting to be sterile are inadequate.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

ID Biomedical Corporation of Quebec findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.